What are the drug interactions of selumetinib/coceyu?

Selumetinib (Selumetinib) is a MEK1/2 inhibitor that mainly reduces tumor growth by inhibiting the MEK pathway. Like all drugs, drug interactions may occur when selumetinib is used in combination with other drugs, affecting its effectiveness or safety in treating neurofibromatosis. Therefore, understanding drug interactions is critical to optimizing treatment.

First, selumetinib may interact with other drugs metabolized by the CYP450 enzyme system. CYP3A4 is the main enzyme in the liver responsible for metabolizing many drugs, so drugs related to CYP3A4 may affect the plasma concentration of selumetinib. Specifically, CYP3A4 inhibitors (such as ketoconazole, clarithromycin, etc.) may reduce the metabolism of selumetinib, leading to an increase in plasma concentrations, thereby increasing the risk of side effects. CYP3A4 inducers (such as carbamazepine, phenobarbital, etc.) may accelerate the metabolism of selumetinib, resulting in weakened drug efficacy.

In addition, selumetinib may interact with other anti-cancer drugs. For example, when used in combination with other MEK inhibitors and BRAF inhibitors, the occurrence of toxic reactions may increase, especially in the skin, gastrointestinal tract, etc. Therefore, when choosing combination drugs, doctors need to comprehensively evaluate the patient's health status and tolerance to avoid excessively increasing the drug burden.

For patients receiving other treatments, especially those with underlying diseases or long-term medication, all medications being used, including prescription drugs, over-the-counter drugs, supplements, etc., must be reported to the doctor when using selumetinib. Certain drugs, especially those that affect the liver enzyme system, may significantly alter the pharmacokinetics of selumetinib, thereby affecting its therapeutic efficacy and side effects.

In summary, the drug interactions of selumetinib are relatively complex. Patients should follow the guidance of their doctors when using selumetinib and avoid combined use with drugs that may cause adverse interactions, such asCYP3A4 inhibitors or inducers.

Keyword tags: selumetinib, coseiyu, drug interaction,CYP3A4, MEK inhibitor, BRAF inhibitor, drug safety

References：https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo